COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The VALIDATE Study of Valsartan for Patients With Early Stage Heart Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00241098
Recruitment Status : Completed
First Posted : October 18, 2005
Last Update Posted : November 8, 2011
Information provided by (Responsible Party):

Brief Summary:
This is a study to evaluate the response of patients with hypertension and early stage heart failure to valsartan.

Condition or disease Intervention/treatment Phase
Hypertension Congestive Heart Failure Drug: valsartan Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 37 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind, Parallel Group Study to Evaluate the Effects of Valsartan Versus Placebo in Patients With Early Stage Heart Failure Due to Diastolic Dysfunction Already Evidenced by an Elevated B-type Natriuretic Peptide Level: the VALIDATE Study
Study Start Date : May 2003
Actual Primary Completion Date : June 2005
Actual Study Completion Date : June 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure
Drug Information available for: Valsartan

Primary Outcome Measures :
  1. Change from baseline in a blood measurement for heart failure after 26 weeks

Secondary Outcome Measures :
  1. Change from baseline in a blood measurement for heart failure after 12 weeks
  2. Change in baseline heart size after 26 weeks
  3. Change in baseline heart size, heart function, and other parameters of diastolic heart dysfunction after 26 weeks
  4. Change from baseline in markers of heart fibrosis after 26 weeks
  5. Change from baseline quality of life questionnaire after 26 weeks

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male or female 25-85 years of age, inclusive
  • Past diagnosis of hypertension for a min 1 year
  • Patients with an established treatment regimen for hypertension with one or more agents for a minimum period of 2 months
  • BP is considered adequately controlled with DBP < 90mmHg
  • Elevated BNP levels both in bedside test (62pg/ml) and after validation of a separate blood sample (40pg/ml) in the central laboratory
  • LV ejection fraction ³ 45%
  • LVH defined as myocardial mass ³ 116 g /m2 in males and 104 g/m2 in females
  • At least one of the following parameters of diastolic dysfunction

    • E/A < 1 for the patients who are younger than 55 years or < 0.8 for the patients whose age is ³ 55 years (full year), or
    • DT > 220 ms, or
    • IVRT > 90 ms

Exclusion Criteria:

• Present use of ACE inhibitor

Other protocol-defined exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00241098

Sponsors and Collaborators
Layout table for investigator information
Study Director: Novartis Pharmaceutical Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: Novartis Identifier: NCT00241098    
Other Study ID Numbers: CVAL489B2402
First Posted: October 18, 2005    Key Record Dates
Last Update Posted: November 8, 2011
Last Verified: February 2006
Keywords provided by Novartis:
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Vascular Diseases
Cardiovascular Diseases
Heart Diseases
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action